Molecular Diagnostics and Treatment Initiation in Tuberculosis

Advances in molecular diagnostics have transformed the identification of Mycobacterium tuberculosis and detection of drug resistance, enabling more rapid and accurate diagnosis than conventional smear microscopy. Polymerase chain reaction (PCR)-based assays, notably the Xpert MTB/RIF Ultra platform, provide results in under two hours and simultaneously test for rifampicin resistance, a key proxy for multidrug-resistant tuberculosis. Deployment of these assays at peripheral health centres, rather than in centralised laboratories, has reduced diagnostic delays and improved linkage to care, facilitating initiation of treatment within days rather than weeks. In parallel, novel isothermal amplification techniques and biosensor-based point-of-care tests are emerging, with the potential to further decentralise testing and extend coverage in resource-limited settings.

Timely treatment initiation following a positive molecular test is critical to reduce morbidity, mortality and onward transmission. Strategies that integrate rapid diagnostics with workflow redesign, performance feedback and decentralised testing infrastructure have demonstrated higher rates of early treatment start. Nonetheless, challenges remain in ensuring sufficient testing volume, maintaining quality assurance, and sustaining supply chains for cartridges and reagents. Clinician decision-making also influences treatment initiation in individuals with negative bacteriological results, with reliance on clinical criteria shaped by the sensitivity of available assays. Overall, molecular diagnostics are reshaping the tuberculosis care continuum, with significant global implications for disease control and patient outcomes.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Molecular Diagnostics and Treatment Initiation in Tuberculosis publication trend

The graph below shows the total number of articles in molecular diagnostics and treatment initiation in tuberculosis across all publications each year (not limited to Nature Index journals).

Technical terms

Xpert MTB/RIF Ultra assay: A cartridge-based, automated PCR test that detects M. tuberculosis complex DNA and rifampicin resistance within two hours.

Decentralised molecular testing: Deployment of molecular diagnostic platforms at peripheral or community health centres rather than central laboratories to shorten turnaround times.

Sputum smear microscopy: Traditional method of tuberculosis diagnosis involving microscopic examination of stained sputum samples for acid-fast bacilli.

Empiric treatment: Initiation of anti-tuberculosis therapy based on clinical assessment and symptoms in the absence of bacteriological confirmation.

References

1. Multicomponent strategy with decentralised molecular testing for tuberculosis in Uganda: a cost and cost-effectiveness analysis. The Lancet Global Health (2023).
2. Impact of a multicomponent strategy including decentralized molecular testing for tuberculosis on mortality: planned analysis of a cluster-randomized trial in Uganda. EClinicalMedicine (2024).
3. Factors associated with tuberculosis treatment initiation among bacteriologically negative individuals evaluated for tuberculosis: An individual patient data meta-analysis.. PLOS Medicine (2025).